重复立体定向放射外科治疗高级别脑膜瘤
本研究回顾性分析2002年至2022年间112例复发或残留高级别脑膜瘤患者接受立体定向放射外科(SRS)的数据,平均随访41.7个月。SRS后肿瘤控制率为29.5%,1、3、5年无进展生存率分别为79.5%、43.8%和30.4%;重复SRS病例分别为97.6%、69%和45.2%。重复SRS的不良放射效应发生率为33.8%,多为无症状。
要点
- SRS对复发或残留高级别脑膜瘤相对安全有效,重复治疗也可接受。
- 间变性表型、次全切除和较大肿瘤体积预示治疗后肿瘤生长。
- 重复SRS后不良放射效应发生率为33.8%,多数无症状。
核心结论
- SRS是复发或残留高级别脑膜瘤相对安全有效的治疗选择,即使重复进行并发症也可接受。
- 间变性肿瘤表型、次全切除和较大肿瘤体积与放疗后肿瘤生长相关,需密切临床监测。
研究设计与样本
- 回顾性分析2002年1月至2022年12月间112例接受SRS的复发或残留高级别脑膜瘤患者的病历数据。
- 患者平均年龄57.9岁,平均随访41.7个月(范围12-160.7个月)。
主要发现
- SRS后中位随访41.7个月时,肿瘤控制率为29.5%。
- Kaplan-Meier分析显示SRS后1、3、5年总无进展生存率分别为79.5%、43.8%和30.4%。
- 重复SRS病例的1、3、5年无进展生存率分别为97.6%、69%和45.2%。
- 男性、年龄较大、间变性表型、次全切除和较大肿瘤体积显著预测治疗后肿瘤生长。
- 重复SRS患者中不良放射效应发生率为33.8%,多数无症状,仅5例需临时激素治疗。
临床怎么用
- 对于复发或残留的高级别脑膜瘤,可考虑SRS治疗,包括重复SRS。
- 对具有间变性表型、次全切除或较大肿瘤体积的患者,SRS后应密切临床监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Atypical and anaplastic meningioma (World Health organization [WHO] Grades II and III) present therapeutic challenges due to their aggressive behavior and high risk of recurrence. This study addressed the lack of data related to the effectiveness and safety of repeated stereotactic radiosurgery (SRS) in managing high-grade recurrent or residual meningioma. METHODS: This study analyzed data extracted from the medical records of 112 patients (mean age of 57.9 years) who underwent SRS for recurrent or residual high-grade meningioma between January 2002 and December 2022. The data included clinicodemographic profiles, treatment parameters, and imaging phenotypes. The average follow-up duration was 41.7 months (range 12-160.7 months). RESULTS: There was slight preponderance of females in the cohort (65:47). All patients had undergone craniotomy and histopathologic confirmation of atypical or anaplastic meningioma. Gross tumor resection was achieved in 35 cases. Atypical meningioma accounted for the vast majority of cases (105; 93.8%) with only 7 cases of anaplastic meningioma (6.2%). At a median follow-up of 41.7 months after SRS, tumor control was achieved in 29.5% of cases. Kaplan-Meier analysis indicated overall actuarial progression free survival rates of 79.5%, 43.8% and 30.4% at 1, 3 and 5 years after radiosurgery, respectively. In cases involving repeated SRS, these rates were 97.6%, 69% and 45.2%, respectively. Male sex, older age, anaplastic phenotype, subtotal resection, and larger tumor volume were significantly predictive of tumor growth after treatment. Adverse radiation effects were observed in 33.8% of patients who underwent repeated SRS. Most of those patients were asymptomatic and only five patients required a temporary course of steroid therapy. CONCLUSIONS: Our data suggest that SRS is a relatively safe and effective treatment option for recurrent or residual high-grade meningioma, with an acceptable complication profile, even when performed repeatedly. Anaplastic tumor phenotype, subtotal resection, and larger tumor volume were factors associated with tumor growth, warranting close clinical surveillance after radiosurgery.
引用
- Peng TC, Hsieh MH, Lin CF, et al. Repeated stereotactic radiosurgery for high grade meningioma. J Neurooncol. 2025. PMID: 40802120. doi:10.1007/s11060-025-05165-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。